Jazz Pharmaceuticals, Inc. (JAZZ) Dividend History

Company News

• Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

  Zymeworks' zanidatamab, a dual HER2-targeted bispecific antibody, has received conditional approval from China's NMPA for the treatment of previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This milestone affirms zanidatamab's clinical potential and Zymeworks' commitment to developing innovative therapies for difficult-to-treat diseases.

  GlobeNewswire Inc.

  Featured Companies: ZYME
• Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

  Zymeworks, a clinical-stage biotechnology company, announced that it will report its Q1 2025 financial results and host a conference call on May 8, 2025. The company also provided updates on its pipeline, including the FDA approval of its HER2-targeted bispecific antibody Ziihera® for second-line biliary tract cancer.

  GlobeNewswire Inc.

  Featured Companies: ZYME
• Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

  Chimerix reported financial results for Q4 and full-year 2024, with a net loss of $23 million and $88.4 million, respectively. The company's NDA for dordaviprone, a treatment for recurrent H3 K27M-mutant diffuse glioma, is under review by the FDA with a PDUFA action date of August 18, 2025. Chimerix is also expected to be acquired by Jazz Pharmaceuticals in Q2 2025.

  GlobeNewswire Inc.
• FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

  The FDA has granted accelerated approval of Ziihera (zanidatamab-hrii), a bispecific HER2-directed antibody, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. This is the first and only dual HER2-targeted bispecific antibody approved for this indication in the U.S.

  GlobeNewswire Inc.

  Featured Companies: ZYME
• Zymeworks Announces Participation in Upcoming Investor Conferences

  Zymeworks, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences, where the company's management will engage in one-on-one meetings and fireside chats to discuss its diverse pipeline of novel biotherapeutics.

  GlobeNewswire Inc.

  Featured Companies: ZYME